Norris Medicines Ltd
Incorporated in 1990, Norris Medicines
Ltd is a manufacturer of Injections and
Medicinal formulations[1]
- Market Cap ₹ 14.4 Cr.
- Current Price ₹ 14.4
- High / Low ₹ 22.1 / 12.5
- Stock P/E
- Book Value ₹ -15.9
- Dividend Yield 0.00 %
- ROCE -10.1 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -5.78% over past five years.
- Promoter holding is low: 34.0%
- Debtor days have increased from 68.4 to 88.4 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.70 | 18.68 | 18.86 | 20.46 | 13.57 | 16.26 | 7.84 | 12.25 | 9.44 | 8.36 | 5.64 | 5.82 | 9.45 | |
| 21.76 | 16.97 | 18.03 | 20.46 | 15.49 | 16.87 | 10.00 | 14.00 | 9.52 | 7.43 | 5.81 | 6.08 | 9.02 | |
| Operating Profit | -1.06 | 1.71 | 0.83 | -0.00 | -1.92 | -0.61 | -2.16 | -1.75 | -0.08 | 0.93 | -0.17 | -0.26 | 0.43 |
| OPM % | -5.12% | 9.15% | 4.40% | -0.00% | -14.15% | -3.75% | -27.55% | -14.29% | -0.85% | 11.12% | -3.01% | -4.47% | 4.55% |
| 0.12 | 0.15 | 0.30 | 0.06 | 0.14 | 0.04 | 0.09 | 0.05 | 0.03 | 0.01 | 0.01 | 0.06 | 0.07 | |
| Interest | 0.45 | 0.54 | 0.67 | 0.60 | 0.70 | 0.73 | 0.88 | 1.63 | 1.48 | 1.50 | 0.37 | 0.44 | 0.50 |
| Depreciation | 1.17 | 1.31 | 0.60 | 0.65 | 0.71 | 0.71 | 0.73 | 0.67 | 0.66 | 0.63 | 0.57 | 0.54 | 0.50 |
| Profit before tax | -2.56 | 0.01 | -0.14 | -1.19 | -3.19 | -2.01 | -3.68 | -4.00 | -2.19 | -1.19 | -1.10 | -1.18 | -0.50 |
| Tax % | -42.97% | 10,500.00% | -128.57% | -35.29% | -21.00% | -16.42% | -22.83% | 24.25% | 49.32% | 47.06% | 8.18% | 5.08% | |
| -1.45 | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.56 | |
| EPS in Rs | -1.45 | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.56 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -6% |
| 3 Years: | -15% |
| TTM: | 106% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 9% |
| 3 Years: | 17% |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 4% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
| Reserves | -3.58 | -4.63 | -4.60 | -5.36 | -7.88 | -9.55 | -12.39 | -17.36 | -20.62 | -22.37 | -23.56 | -24.79 | -25.82 |
| 7.52 | 8.16 | 7.51 | 7.57 | 7.71 | 11.24 | 17.92 | 15.52 | 21.08 | 21.40 | 21.52 | 21.58 | 21.47 | |
| 7.45 | 4.69 | 5.06 | 9.90 | 10.92 | 8.76 | 5.10 | 11.69 | 3.80 | 4.72 | 6.29 | 7.09 | 7.91 | |
| Total Liabilities | 21.32 | 18.15 | 17.90 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 | 13.49 |
| 8.97 | 8.61 | 8.34 | 9.97 | 9.32 | 8.90 | 8.25 | 7.67 | 7.07 | 6.47 | 5.79 | 5.27 | 5.03 | |
| CWIP | 0.10 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| 12.24 | 9.53 | 9.55 | 12.06 | 11.35 | 11.47 | 12.30 | 12.10 | 7.11 | 7.20 | 8.38 | 8.53 | 8.45 | |
| Total Assets | 21.32 | 18.15 | 17.90 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 | 13.49 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.44 | -1.43 | 1.35 | -0.96 | 0.80 | -1.92 | -2.88 | 1.11 | -1.01 | 1.20 | 0.17 | 0.51 | |
| -1.75 | -0.88 | -0.34 | -2.05 | -0.08 | -0.29 | -0.00 | -0.06 | -0.09 | -0.02 | 0.05 | -0.00 | |
| 0.02 | 0.10 | -1.32 | 3.16 | -0.66 | 2.18 | 2.86 | -1.09 | 1.10 | -1.18 | -0.20 | -0.50 | |
| Net Cash Flow | -0.28 | -2.21 | -0.31 | 0.15 | 0.06 | -0.02 | -0.02 | -0.04 | -0.00 | -0.00 | 0.02 | -0.00 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91.34 | 73.66 | 53.61 | 84.20 | 66.44 | 67.57 | 128.49 | 53.33 | 42.15 | 48.03 | 68.60 | 88.43 |
| Inventory Days | 74.17 | 100.05 | 134.23 | 129.50 | 238.53 | 134.81 | 323.82 | 212.99 | 157.45 | 347.62 | 594.15 | 436.94 |
| Days Payable | 151.02 | 111.66 | 99.30 | 125.29 | 252.40 | 139.83 | 233.37 | 218.83 | 86.53 | 149.91 | 244.25 | 271.90 |
| Cash Conversion Cycle | 14.50 | 62.06 | 88.54 | 88.41 | 52.56 | 62.55 | 218.94 | 47.49 | 113.06 | 245.73 | 418.51 | 253.47 |
| Working Capital Days | 12.87 | 27.75 | 34.84 | -16.06 | -91.18 | -32.55 | -30.73 | -103.69 | -97.82 | -122.25 | -202.56 | -241.45 |
| ROCE % | 4.02% | 4.03% | -4.08% | -22.92% | -11.97% | -20.68% | -20.13% | -7.68% | 3.20% | -8.43% | -10.13% |
Documents
Announcements
-
Outcome Of The Board Meeting Held On 14Th February, 2026 Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
1d - Board approved unaudited financial results with limited review for quarter and year ended 31-Dec-2025.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14Th February, 2026 Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
1d - Board approved unaudited financial results and limited review for quarter/year ended 31 Dec 2025.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Closure Of Case ID 223728 For Reclassification Of Promoter.
2d - BSE closed Case ID 223728 on 12-Feb-2026; promoter classification remains unchanged due to disputed penalty non-payment.
-
Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements, 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended December 31St, 2025 And Other Matters.
11 Feb - Board meeting on Feb 14, 2026 to approve Q3 and nine-month unaudited results (Dec 31, 2025); trading window closed.
-
Announcement under Regulation 30 (LODR)-Change in Management
4 Feb - CFO Iqubal Patel resigned effective Feb 03, 2026; company to appoint replacement; resignation for personal reasons.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2000
from bse
-
Financial Year 1998
from bse
Business Overview:[1]
NML is engaged in the healthcare business.
It carries out contract manufacturing and License Manufacturing for large Multinational
and big Indian Pharma Companies.